KAI banks $13M in development deal with Japan's Ono

South San Francisco-based KAI Pharmaceuticals has inked a Japanese development and marketing deal for its lead therapy, nabbing a $13 million upfront payment from Ono Pharmaceutical. Now nearing the end of a Phase II study, KAI-4169 is being tested as an IV drug for secondary hyperparathyroidism in patients with chronic kidney disease-mineral and bone disorder. Ono gets the Japanese rights to...